Published in Br J Pharmacol on July 01, 1982
Antihemostatic, antiinflammatory, and immunosuppressive properties of the saliva of a tick, Ixodes dammini. J Exp Med (1985) 1.97
Purinergic signalling and immune cells. Purinergic Signal (2014) 0.94
Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature (1980) 9.25
Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest (1977) 5.16
Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol (1977) 2.26
Evidence that prostaglandin is responsible for the 'rebound contraction' following stimulation of non-adrenergic, non-cholinergic ('purinergic') inhibitory nerves. Eur J Pharmacol (1975) 2.09
Stimulation of prostaglandin biosynthesis by adenine nucleotides. Profile of prostaglandin release by perfused organs. Circ Res (1974) 1.97
Purinergic receptors. J Theor Biol (1976) 1.79
Effects of adenosine 5'-triphosphate (ATP) and beta-gamma-methylene ATP on the rat urinary bladder. Br J Pharmacol (1979) 1.76
1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. Am J Pathol (1981) 1.56
The effects of some antirheumatic drugs on an in vitro model of human polymorphonuclear leucocyte chemokinesis. Br J Pharmacol (1980) 1.33
Effect of exogenous cyclic AMP and other adenine nucleotides on neutrophil chemotaxis and motility. Int Arch Allergy Appl Immunol (1976) 1.25
Substances which aggregate neutrophils. Mechanism of action. Am J Pathol (1978) 1.19
Aggregation of rat polymorphonuclear leucocytes in vitro. J Pharm Pharmacol (1980) 1.14
Phorbol myristate acetate: in vivo effects upon neutrophils, platelets, and lung. Am J Pathol (1980) 1.11
Migration of peritoneal polymorphonuclear leucocytes in the rat. J Pathol (1979) 1.11
Evidence for 5, 12-dihydroxy-6,8,10,14-eicosatetraenoate as a mediator of human neutrophil aggregation. Biochem Biophys Res Commun (1981) 0.98
Arachidonic acid aggregates neutrophils. Inflammation (1979) 0.90
The aggregation of rat neutrophils by arachidonic acid: a possible bioassay for lipoxygenase activity. J Pharm Pharmacol (1979) 0.84
Calcium ion-dependent adenosine triphosphatase activity and plasma-membrane phosphorylation in the human neutrophil. Biochem J (1979) 0.83
Phospholipid metabolism and lysosomal enzyme secretion by leukocytes. Effects of dibutyryl cyclic adenosine 3':5'-monophosphate and ATP. Biochim Biophys Acta (1976) 0.83
Contraction and volume changes of glycerol treated rabbit polymorphonuclear leukocytes induced by ATP and Ca 2 ion. Proc Soc Exp Biol Med (1974) 0.83
Calcium ionophore A23187 induces release of chemokinetic and aggregating factors from polymorphonuclear leucocytes. Br J Pharmacol (1980) 0.79
Effects of adenosine analogs and adenine nucleotides on adenosine 5'-diphosphate-induced rat platelet aggregation. Biochem Pharmacol (1980) 0.78
Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature (1980) 9.25
Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature (1999) 3.57
Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett (1993) 2.41
The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol (1984) 2.25
Identification and isolation of a membrane protein necessary for leukotriene production. Nature (1990) 2.20
MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem (1990) 2.14
Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol (1980) 2.13
L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol (1989) 1.88
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther (2001) 1.65
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther (1999) 1.63
Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis (1991) 1.59
Leukotriene B4: a mediator of vascular permeability. Br J Pharmacol (1981) 1.57
Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol (1989) 1.50
Leukotriene B4: an inflammatory mediator in vivo. Prostaglandins (1981) 1.48
Anti-inflammatory drugs, prostaglandins and leucocyte migration. Agents Actions (1976) 1.45
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol (1997) 1.44
Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol (1995) 1.41
Alclofenac and D-penicillamine. Comparative trial in rheumatoid arthritis. Ann Rheum Dis (1978) 1.38
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther (1995) 1.37
Isomers of leukotriene B4 possess different biological potencies. Prostaglandins (1981) 1.33
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett (1999) 1.30
Leukotrienes: their formation and role as inflammatory mediators. Fed Proc (1985) 1.24
Effects of a human plasma fraction on leucocyte migration into inflammatory exudates. J Pharm Pharmacol (1975) 1.23
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation (1992) 1.18
Purification to homogeneity and the N-terminal sequence of human leukotriene C4 synthase: a homodimeric glutathione S-transferase composed of 18-kDa subunits. Proc Natl Acad Sci U S A (1993) 1.15
Mode of action of an anti-inflammatory fraction from normal human plasma. Nature (1975) 1.15
Relaxant profile of synthetic atrial natriuretic factor on guinea-pig pulmonary tissues. Eur J Pharmacol (1986) 1.14
Migration of peritoneal polymorphonuclear leucocytes in the rat. J Pathol (1979) 1.11
The production and characterisation of products of the lipoxygenase enzyme system released by rat peritoneal macrophages. Prostaglandins (1980) 1.09
Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol (1998) 1.08
Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am Rev Respir Dis (1992) 1.08
Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol (1992) 1.08
Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities. J Biol Chem (1997) 1.08
The nucleotide sequence of a voltage-gated chloride channel from the electric organ of Torpedo californica. Biochim Biophys Acta (1991) 1.06
The binding of paracetamol to plasma proteins of man and pig. J Pharm Pharmacol (1973) 1.06
Leukotriene A3. A poor substrate but a potent inhibitor of rat and human neutrophil leukotriene A4 hydrolase. J Biol Chem (1985) 1.06
L-649,923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)- gamma-hydroxy-beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist. Can J Physiol Pharmacol (1986) 1.04
The effects of D-pencillamine and levamisole on leucocyte chemotaxis in the rat. Br J Pharmacol (1978) 1.01
PGI2: a potential mediator of inflammation. Prostaglandins (1978) 1.00
Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol Pharmacol (1992) 0.98
A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. Eur J Pharmacol (1999) 0.96
Comparative biological activities of synthetic leukotriene B4 and its omega-oxidation products. Prostaglandins (1983) 0.96
Leukotriene A5 is a substrate and an inhibitor of rat and human neutrophil LTA4 hydrolase. Biochem Biophys Res Commun (1985) 0.96
Prostaglandins and the anti-inflammatory activities of aspirin and sodium salicylate. J Pharm Pharmacol (1975) 0.95
Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist. Eur J Pharmacol (1987) 0.95
Anti-inflammatory activity of bacterial endotoxin. J Pharm Pharmacol (1977) 0.94
Activation of protein kinase C down-regulates leukotriene C4 synthase activity and attenuates cysteinyl leukotriene production in an eosinophilic substrain of HL-60 cells. J Immunol (1994) 0.94
Purification of human leukotriene C4 synthase from dimethylsulfoxide-differentiated U937 cells. Eur J Biochem (1992) 0.93
Production of leukotriene C4 in different human tissues is attributable to distinct membrane bound biosynthetic enzymes. J Biol Chem (1997) 0.93
Human leukotriene C4 synthase expression in dimethyl sulfoxide-differentiated U937 cells. J Biol Chem (1992) 0.92
Differing mechanisms for leukotriene d4-induced bronchoconstriction in guinea pigs following intravenous and aerosol administration. Prostaglandins (1982) 0.92
Antirheumatic activity of fenclofenac. Ann Rheum Dis (1980) 0.91
Purification and characterisation of leukotriene A4 hydrolase from rat neutrophils. Biochim Biophys Acta (1985) 0.90
Inhibition of prostanoid-mediated platelet aggregation in vivo and in vitro by 3-hydroxymethyl-dibenzo(b,f)thiepin 5,5-dioxide (L-640,035). J Pharmacol Exp Ther (1984) 0.89
Leukotriene B4, polymorphonuclear leukocytes and inflammatory exudates in the rat. Prostaglandins (1984) 0.89
The binding of scandium ions to transferrin in vivo and in vitro. Eur J Biochem (1971) 0.89
Bronchoconstriction induced by N-formyl-methionyl-leucyl-phenylalanine in the guinea pig; involvement of arachidonic acid metabolites. Prostaglandins (1984) 0.89
Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome. Am Rev Respir Dis (1991) 0.89
Leukotriene B4 and neutrophil function: a review. J R Soc Med (1981) 0.88
Leukotrienes C4 and D4 in psoriatic skin lesions. Prostaglandins (1985) 0.88
Platelets, prostaglandins and inflammation. Agents Actions (1976) 0.87
Prostaglandin and thromboxane production by rabbit polymorphonuclear leukocytes and rat macrophages. Adv Prostaglandin Thromboxane Res (1980) 0.86
Detection of leukotriene C4-liked immunoreactivity in tear fluid from subjects challenged with specific allergen. Prostaglandins (1984) 0.86
Aspirin, salicylate and prostaglandins. Agents Actions (1979) 0.86
Regulation of leukotriene-biosynthetic enzymes during differentiation of myelocytic HL-60 cells to eosinophilic or neutrophilic cells. Eur J Biochem (1996) 0.86
Molecular cloning and functional expression of a Caenorhabditis elegans aminopeptidase structurally related to mammalian leukotriene A4 hydrolases. J Biol Chem (1998) 0.86
Neutrophil aggregating and chemokinetic properties of a 5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid isolated from human leukocytes. Prostaglandins (1982) 0.85
Anti-inflammatory activity in human plasma. J Pharm Pharmacol (1973) 0.85
The aggregation of rat neutrophils by arachidonic acid: a possible bioassay for lipoxygenase activity. J Pharm Pharmacol (1979) 0.84
Contractile activity of calcitonin gene-related peptide on pulmonary tissues. J Pharm Pharmacol (1988) 0.84
Responses of equine trachealis and lung parenchyma to methacholine, histamine, serotonin, prostanoids, and leukotrienes in vitro. Can J Physiol Pharmacol (1990) 0.84
Late pulmonary responses induced by Ascaris allergen in conscious squirrel monkeys. J Appl Physiol (1985) (1986) 0.83
Prostaglandins and leucotaxis. J Pharm Pharmacol (1976) 0.83
Synthesis and biological activities of leukotriene F4 and leukotriene F4 sulfone. Prostaglandins (1982) 0.83
Inflammation and pain sensitivity: effects of leukotrienes D4, B4 and prostaglandin E1 in the rat paw. Prostaglandins (1983) 0.83
Characterization of arachidonic-acid-metabolizing enzymes in adult Schistisoma mansoni. Mol Biochem Parasitol (1995) 0.83
Elevated cysteinyl leukotriene excretion in experimental glomerulonephritis. Kidney Int (1994) 0.82
Prostaglandins and leucocyte migration in inflammatory reactions. Agents Actions (1977) 0.82
Separate anti-inflammatory effects of indomethacin, flurbiprofen and benoxaprofen. J Pharm Pharmacol (1977) 0.82
Leukotriene B3, leukotriene B4 and leukotriene B5; binding to leukotriene B4 receptors on rat and human leukocyte membranes. Prostaglandins (1986) 0.82
L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)- propylsulfonyl]-gamma-oxo-benzenebutanoate: a leukotriene D4 receptor antagonist. Can J Physiol Pharmacol (1986) 0.82
L-651,392: a novel, potent and selective 5-lipoxygenase inhibitor. Adv Prostaglandin Thromboxane Leukot Res (1987) 0.82
Leukotriene involvement in pathologic processes. J Allergy Clin Immunol (1984) 0.81
Respiratory responses to leukotrienes and biogenic amines in normal and hyperreactive rats. J Immunol (1983) 0.81
Prostaglandins and the anti-inflammatory activity of a human plasma fraction in carrageenan-induced paw oedema in the rat. J Pharm Pharmacol (1974) 0.81
The human prostanoid DP receptor stimulates mucin secretion in LS174T cells. Br J Pharmacol (2000) 0.81
The destruction of cytochrome P-450 by alclofenac: possible involvement of an epoxide metabolite. Biochem Pharmacol (1982) 0.81
BQ-153, a novel endothelin (ET)A antagonist, attenuates the renal vascular effects of endothelin-1. J Pharm Pharmacol (1992) 0.81
Studies on L-640,035: a novel antagonist of contractile prostanoids in the lung. Br J Pharmacol (1984) 0.81
Neutrophil aggregating properties of PAF-acether and leukotriene B4. Int J Immunopharmacol (1983) 0.80
Effect of altitude on urinary leukotriene (LT) E4 excretion and airway responsiveness to histamine in children with atopic asthma. Eur Respir J (1995) 0.80
Production of leukotrienes in human skin and conjunctival mucosa after specific allergen challenge. Allergy (1985) 0.80
Effects of a human plasma fraction on the release of chemotactic factors and anaphylatoxin from complement. J Pharm Pharmacol (1975) 0.80
Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives. J Med Chem (1995) 0.80
Generation of leukotriene B4, its all trans isomers and 5-hydroxyeicosatetraenoic acid by rat basophilic leukaemia cells. Br J Pharmacol (1982) 0.79
L-641,953 (R-8-fluoro-dibenzo[b, f]thiepin-3-carboxylic acid-5-oxide): a novel thromboxane-prostaglandin endoperoxide antagonist. Can J Physiol Pharmacol (1987) 0.79
Thromboxane A2 and prostaglandin endoperoxide analogue effects on porcine renal blood flow. Am J Physiol (1990) 0.79
Calcium ionophore A23187 induces release of chemokinetic and aggregating factors from polymorphonuclear leucocytes. Br J Pharmacol (1980) 0.79
Biological activities of isomers of 8,15-dihydroxyeicosatetraenoic acid. Prostaglandins (1984) 0.79